Cerebrospinal Fluid Biomarkers for Brain Tumors

This observational study is collecting cerebrospinal fluid (CSF) samples from people with brain tumors. CSF is the fluid surrounding your brain and spinal cord. Researchers hope to find "biomarkers" – measurable indicators of disease – in these samples that could help doctors better diagnose, monitor, and treat brain tumors. The study aims to gather enough samples to be a valuable resource for the research community. You may be eligible if you are 18 years or older and have any type of tumor involving your central nervous system (brain, spine, or surrounding structures). The study is currently unclear on its recruitment status and plans to enroll 400 participants.

Study design: This is an observational study with a planned enrollment of 400 participants. It is not a treatment study.
What's involved: You would undergo collection of CSF samples via lumbar puncture at least two times. You may also choose to provide additional CSF samples.
Compensation: Not stated in the trial record.
Follow-up: After completion of study treatment, patients are followed up periodically.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Cerebrospinal Fluid Biomarkers for Brain Tumors

Recruiting

Not specifiedAll AgesObservational

Mayo Clinic

~400 participants

Updated 2026-04-22 on ClinicalTrials.gov

What's tested:Biospecimen CollectionElectronic Health Record Review

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Collection cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery

Measured over Up to study completion

Conditions

Central Nervous System Neoplasm

Where it's being run

1 sites across 1 states

Minnesota1

Study leadership

Terry C. Burns, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office

[email protected]

855-776-0015

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures

Subjects must be 18 years of age or older

Exclusion

Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study

Pregnant women or women who may be pregnant are specifically excluded from study participation

Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available

Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded

Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded

Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access

What this trial measures

Collection cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discoveryUp to study completion

Trialytics